Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$71.21 USD

71.21
1,481,609

-0.73 (-1.01%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $71.19 -0.02 (-0.03%) 6:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (170 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

by Zacks Equity Research

Glaukos Corporation (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.

Fresenius Medical's (FMS) Deal to Boost Home Dialysis in Japan

by Zacks Equity Research

Fresenius Medical (FMS) partners with JMS Co. Ltd. to provide innovative home dialysis therapies to the aging population in Japan to improve their wellbeing.

Here's Why You Should Retain Abiomed (ABMD) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Abiomed (ABMD) owing to its strength in the Impella product line.

PerkinElmer (PKI) to Benefit From BioLegend Buyout: Here's How

by Zacks Equity Research

PerkinElmer's (PKI) latest acquisition is likely to expand its life science business and enhance its reagents portfolio.

Henry Schein (HSIC) Betters Strategic View With Restructure Plan

by Zacks Equity Research

Henry Schein's (HSIC) new organizational structure will continue to enhance the company's exposure to faster-growing and higher-margin markets.

NextGen's (NXGN) New Collaboration to Boost Solutions Portfolio

by Zacks Equity Research

NextGen (NXGN) and Klamath partner to deliver large-scale COVID-19 vaccinations.

Debanjana Dey headshot

Cybersecurity Gains Prominence in MedTech: 3 Stocks to Focus on

by Debanjana Dey

Technology-based healthcare stocks like Henry Schein (HSIC), Veeva Systems (VEEV) and BD (BDX) are expected to continue their rally over the next few months.

Align Technology (ALGN) Launches Professional Whitening System

by Zacks Equity Research

Align Technology's (ALGN) Invisalign Professional Whitening System transforms teeth whitening with an all-in-one solution, enabling Invisalign doctors to straighten and whiten teeth simultaneously.

The Zacks Analyst Blog Highlights: Align Technology, West Pharmaceutical Services, Henry Schein and Merit Medical Systems

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Align Technology, West Pharmaceutical Services, Henry Schein and Merit Medical Systems

Syneos Health's (SYNH) New Buyout Boosts Clinical Solutions Arm

by Zacks Equity Research

Syneos Health (SYNH) acquisition of StudyKIK strengthens the former's ability to provide technology and insight-driven solutions.

Here's Why You Should Retain Catalent (CTLT) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals and product launches.

Trina Mukherjee headshot

3 Dental Stocks Poised to Perform Well in Second-Half 2021

by Trina Mukherjee

Let's keep a watch on three lucrative stocks, WST, HSIC and MMSI, in the dental space that investors can add to their watchlist backed by robust long-term prospects.

Accuray's (ARAY) CyberKnife Favored For Prostate Cancer Treatment

by Zacks Equity Research

Per the PACE trial data, patients treated with Accuray's (ARAY) CyberKnife SBRT are likely to experience lesser bladder-related side effects unlike conventional linear accelerator.

OPKO Health (OPK) Forms JV, Establishes Presence in China

by Zacks Equity Research

OPKO Health (OPK) forms a new JV with LeaderMed to establish a presence in China through expansion of the global availability of two of the former's long-acting development products.

Medtronic's (MDT) Pilot Plan to Address SCA Care Disparities

by Zacks Equity Research

Medtronic's (MDT) pilot program offers an advanced and scalable method to use real-world clinical data which enable quicker and appropriate care for patients at-risk of SCA.

Dexcom's (DXCM) G6 CGM Under NIHB Program to Aid More Patients

by Zacks Equity Research

Expanded access to Dexcom's (DXCM) G6 CGM for clients enrolled in NIHB is expected to aid a wider patient pool to better manage their diabetes.

Tandem Diabetes (TNDM) Rides on Innovation Despite Cost Woes

by Zacks Equity Research

Continued adoption of Tandem Diabetes' (TNDM) t:slim X2 insulin pumps by both new and existing users is encouraging.

Here's Why You Should Retain CONMED (CNMD) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.

Here's Why You Should Invest in Intuitive Surgical (ISRG) Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vince Surgical System.

Masimo (MASI) Launches SuperSensor, Boosts Product Profile

by Zacks Equity Research

Masimo's (MASI) launch of SuperSensor can help clinicians to continuously monitor patients through one comprehensive, convenient, noninvasive fingertip solution.

LabCorp (LH) Bolsters RA Testing by Adding Myriad's Vectra

by Zacks Equity Research

According to LabCorp (LH), Vectra and the related IP and other assets from Myriad Genetics' autoimmune business complement its prior business activity.

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

LHC Group (LHCG) to Boost Nationwide Presence With New Buyout

by Zacks Equity Research

LHC Group's (LHCG) deal win enables the company to acquire home health, hospice and therapy assets in 22 states.

Abbott (ABT) Nutrition Sales Grow Despite Pandemic Woes

by Zacks Equity Research

Abbott's (ABT) Sales of Pedialyte, the global rehydration brand, strongly grows driven by the recently launched products and increased investments in direct consumer promotion.

Here's Why You Should Retain Allscripts (MDRX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and solid prospects of the Sunrise EHR platform.